Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

recensmedical.com

Stage

Series A | Alive

Total Raised

$6.83M

Last Raised

$5.9M | 3 yrs ago

About RecensMedical

RecensMedical is a health-tech company that develops cooling anesthesia which can be used in painless intravitreal injection therapy, painless laser therapy and needle injections.

RecensMedical Headquarters Location

50 UNIST-gil, Eonyang-eup Suite 301-1

Ulsan, 44919,

South Korea

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing RecensMedical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RecensMedical is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,490 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

RecensMedical Patents

RecensMedical has filed 13 patents.

The 3 most popular patent topics include:

  • Anesthesia
  • Cooling technology
  • Thermodynamics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/16/2020

4/12/2022

Cooling technology, Thermodynamic cycles, Thermodynamics, Sustainable building, Gas technologies

Grant

Application Date

6/16/2020

Grant Date

4/12/2022

Title

Related Topics

Cooling technology, Thermodynamic cycles, Thermodynamics, Sustainable building, Gas technologies

Status

Grant

Latest RecensMedical News

Kodiak Sciences : 22nd EURETINA Presentation

Sep 2, 2022

09/02/2022 | 11:09am EDT Message : Primary 24-Week Efficacy and Safety Outcomes of the BEACON Phase 3 Pivotal Study Arshad M. Khanani, M.D., M.A., FASRS Director of Clinical Research, Sierra Eye Associates, Reno, NV USA on behalf of the BEACON Study Group 2 September 2022 Presenter's Financial Disclosures: Consultant: Abbvie, Adverum, AGTC, Aldebaran Therapeutics, Alimera, Apellis, Arrowhead, Asclepix, Aviceda, Bausch and Lomb, Broadwing Bio, Cholgene, 4DMT, Eyepoint, Frontera Therapeutics, Gemini, Genentech, Inc., Graybug, Gyroscope, Iveric Bio, Janssen, Kartos Therapeutics, Kato Pharma, Kodiak, Kriya Therapeutics, Ocular Therapeutix, Oculis, Ocuterra, Opthea, Oxurion, Nanoscope, Novartis, Perfuse, PolyPhotonix, Protagonist, Ray Therapeutics, Recens Medical, Regeneron, Retrotope, Regenxbio, RevOpsis, Roche, Stealth, Thea, Unity Bio, Vanotech, Vial Research Support: Adverum, Alkahest, Annexon, Apellis, Asclepix, 4DMT, Gemini, Genentech, Inc., Graybug Vision, Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Ocular Therapeutix, Oculis, Ocuterra, Opthea, Oxurion, Novartis, Recens Medical, Regenxbio, Roche, Unity Bio Speaker: Abbvie, Apellis, Bausch and Lomb, Genentech, Inc., Novartis Equity: Aviceda, Recens Medical, Retrotope, RevOpsis, PolyPhotonix This presentation will discuss IRB/IEC approved research of an investigational medicine. 2 # Injections in first 6 months Monthly dosing is difficult to achieve in clinical practice, where 72% of patients received less than monthly dosing. With currently available anti-VEGFs, treatment less often than monthly compromises vision outcomes in RVO A less frequent therapy that achieves comparable outcomes would be an important advance Adapted from Ciulla T, et al. Br J Ophthalmol 2021;105:1696-1704.doi:10.1136/bjophthalmol-2020-317337. Represents 8,876 BRVO eyes, 6,737 CRVO eyes from Vestrum database. Mean 4.5 and 4.6 anti-VEGF injections over first 6 3 months (aflibercept, ranibizumab, or bevacizumab) in BRVO and CRVO, respectively. VA, Visual acuity. RVO, retinal vein occlusion. BRVO, branch retinal vein occlusion. CRVO, central retinal vein occlusion. KSI-301 (tarcocimab tedromer): Antibody Biopolymer Conjugates (ABCs) A novel class of biologics engineered for increased durability and efficacy +=

RecensMedical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

RecensMedical Rank

  • Where is RecensMedical's headquarters?

    RecensMedical's headquarters is located at 50 UNIST-gil, Eonyang-eup, Ulsan.

  • What is RecensMedical's latest funding round?

    RecensMedical's latest funding round is Series A.

  • How much did RecensMedical raise?

    RecensMedical raised a total of $6.83M.

  • Who are the investors of RecensMedical?

    Investors of RecensMedical include LB Investment, Hyundai Venture Investment Corporation, Lighthouse Combined Investment, TIPS Program, Korea Technology Investment Corporation and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.